Monoclonal antibody · Antagonist of Tissue factor pathway inhibitor (TFPI) · developed by Novo Nordisk
Concizumab is a monoclonal antibody that binds and antagonizes endogenous tissue factor pathway inhibitor (TFPI), enhancing factor Xa production and thrombin generation during the initiation of coagulation. It is studied in congenital haemophilia. Its effect does not depend on FVIII or FIX inhibitory antibodies.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 1, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04921956 | N/A | Congenital Haemophilia | No longer available | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Congenital Haemophilia
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →